Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Biotechnology

Healthcare
$95.05 +0.77%

+$0.42 today

Market cap
$7.47B
Beta
0.12
P/E (TTM)
57.2
EPS (TTM)
$0.95
52W Low $26.27High $59.87

Volume 0.33M

Average 0.66M

KNSA Sales of Investments

Cash received from selling or redeeming investments.

Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments grows, but more slowly than its trailing trend

Q2 FY2026 sales of investments of $36.7M rose 19.9% year over year, behind the +65.4% change in trailing-twelve-month sales of investments. Sequentially, it fell 74.8% from the prior quarter. Over 3 fiscal years it compounded at +23.4% a year.

Context

  • Sales of investments amounted to 35.4% of revenue in FY2025, down 21.3 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +19.9% toward the trailing-twelve-month pace of +65.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$36.7M-74.8% QoQ
Last fiscal yearDec 2025
$239.94M+0.0% YoY
LTMJun 2026
$347.66M+65.4% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.9%——
1 year+0.0%——
3-year CAGR+23.4%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
239.94M USD
Year-over-year change
+0.0%
4-year CAGR
-5.9%

Sales of Investments vs competitors

How KNSA compares with its peers on the latest reported figures

  • KNSA's LTM Jun 2026 sales of investments of $347.66M is the 5th largest of the 10 companies compared; the peer median is $322.1M.
  • Its year-over-year change of +65.4% is the 2nd highest of 8, against a peer median of +3.0%.
  • Sales of investments amounts to 41.3% of revenue for KNSA, versus a peer median of 315.7%.
KNSA Competitors Peer median
Sales of Investments for KNSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$614.95M +3.0%+30.4%87.6%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$445.96M +31.2%+56.7%492.8%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$405.29M +102.6%——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$362.7M +47.6%+438.5%19049.4%
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 2026$347.66M +65.4%+23.4%41.3%
ANABAnaptysBio, Inc.LTM Mar 2026$322.1M -33.7%+1.3%138.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$79.8M -19.5%-20.6%953.7%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$46.7M ——79155.9%
PHARPharming Group N.V.LTM Mar 2026$34.98M -87.9%—9.5%
IMVTImmunovant, Inc.LTM Sep 2026$0 ——0.0%
Peer median (excluding KNSA) $322.1M+3.0%+30.4%315.7%

Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(157.92M)183.36M14.08M(43.19M)(43.19M)
Depreciation & Amortization2.36M2.4M2.34M1.7M1.55M
Deferred Income Tax11K(185.5M)(33.79M)8.13M8.13M
Stock-Based Compensation25.17M25.12M27.15M30.69M30.69M
Change in Working Capital689K(22.58M)1.35M24.81M51.63M
Accounts Receivables(3.91M)(16.33M)(950K)(20.46M)26.13M
Inventory(3.68M)(17.92M)(9.52M)4.76M4.76M
Accounts Payables1.37M6.03M347K(6.31M)(6.31M)
Other Working Capital6.91M5.65M11.48M46.82M27.05M
Other Non-Cash Items3.4M2.99M2.17M3.55M(23.13M)
Operating Cash Flow(126.3M)5.81M13.3M25.69M25.69M
Capital Expenditures(20.42M)(105K)(130K)(277K)(277K)
Acquisitions (Net)00025K0
Purchases of Investments(157.25M)(135.86M)(204.93M)(202.01M)(202.01M)
Sales of Investments306.3M127.8M175.51M239.94M239.94M
Other Investing Activities(20M)91K0025K
Investing Cash Flow128.64M(8.08M)(29.56M)37.67M37.67M
Debt Repayment00000
Common Stock Issued5.89M3.42M000
Common Stock Repurchased00(2.21M)(4.98M)(7.73M)
Dividends Paid00000
Other Financing Activities0(901K)3.7M17.25M20M
Financing Cash Flow5.89M2.52M1.5M12.27M12.27M
Effect of Forex Changes00000
Net Change in Cash8.22M245K(14.76M)75.63M75.63M
Free Cash Flow(146.71M)5.7M13.17M25.41M25.41M

Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Intrinsic Alpha fair value

Locked

Current Price

$95.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.